文献速递炎症性肠病

硫唑嘌呤类药物对溃疡性结肠炎自然病史及手术结局的影响:一项队列研究

Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study.
PubMed 文献 · Gut · 2018-04-04

该队列研究纳入1963-2010年瑞典厄勒布鲁大学医院辖区确诊的溃疡性结肠炎并启用硫唑嘌呤类药物的253例患者,通过比较因不良反应12个月内停药者与继续用药或其他原因停药者,评估10年内结肠切除、住院、病变范围进展及抗TNF治疗情况,发现耐受者上述结局均优于不耐受者。

要点

  • 10年结肠切除累积概率耐受者19.5% vs 不耐受者29.0%,校正HR 0.49(95%CI 0.21-0.73)。
  • 10年住院概率耐受者34.0% vs 不耐受者56.2%,校正HR 0.36(95%CI 0.23-0.56)。
  • 10年抗TNF治疗比例耐受者16.1% vs 不耐受者27.5%,校正HR 0.49(95%CI 0.26-0.92)。

核心结论

  • 基于比较硫唑嘌呤耐受与不耐受患者的新方法,硫唑嘌呤对溃疡性结肠炎的自然病史和长期结肠切除率有深远的有益影响。

研究设计与样本

  • 纳入1963-2010年瑞典厄勒布鲁大学医院辖区确诊的溃疡性结肠炎并启用硫唑嘌呤类药物的患者253例。
  • 比较因不良反应12个月内停药者76例与继续治疗或其他原因停药者177例,采用Cox回归校正潜在混杂因素评估长期结局。

主要发现

  • 10年内结肠切除累积概率耐受者19.5% vs 不耐受者29.0%,校正HR 0.49(95%CI 0.21-0.73)。
  • 10年内住院概率耐受者34.0% vs 不耐受者56.2%,校正HR 0.36(95%CI 0.23-0.56)。
  • 病变范围进展风险耐受者20.4% vs 不耐受者48.8%,校正HR 0.47(95%CI 0.21-1.06),未达统计学显著。
  • 10年内接受抗TNF治疗比例耐受者16.1% vs 不耐受者27.5%,校正HR 0.49(95%CI 0.26-0.92)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Thiopurines are used as maintenance therapy in ulcerative colitis (UC), but whether these drugs influence the natural history of the disease is unknown. We aimed to assess the effect of thiopurines in terms of colectomy, hospital admission, progression in disease extent and anti-tumour necrosis factor (TNF) therapy within 10 years from initiation. DESIGN: Patients diagnosed with UC within the Örebro University Hospital catchment area, during 1963-2010, who initiated thiopurines (n=253) were included. To overcome the risk of confounding by indication, we compared patients who stopped treatment within 12 months because of an adverse reaction (n=76) with patients who continued therapy or discontinued due to other reasons (n=177) and assessed long-term outcomes using Cox regression with adjustment for potential confounding factors. RESULTS: The cumulative probability of colectomy within 10 years was 19.5% in tolerant patients compared with 29.0% in intolerant (adjusted HR 0.49; 95% CI 0.21 to 0.73). The probability of hospital admission was 34.0% in tolerant versus 56.2% in intolerant patients (adjusted HR 0.36; 95% CI 0.23 to 0.56). The risk for progression in disease extent was 20.4% in tolerant patients compared with 48.8% in intolerant (adjusted HR 0.47; 95% CI 0.21 to 1.06). Within 10 years, 16.1% of tolerant and 27.5% of intolerant patients received anti-TNF therapy (adjusted HR 0.49; 95% CI 0.26 to 0.92). CONCLUSION: Based on the novel approach of comparing patients tolerant and intolerant to thiopurines, we reveal that thiopurines have a profound beneficial impact of the natural history and long-term colectomy rates of UC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Eriksson C, Rundquist S, Cao Y, et al. Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. Gut. 2018. PMID: 29618498. doi:10.1136/gutjnl-2017-315521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。